Table 2.
Characteristics and symptoms of patients with organizing pneumonia (n = 849).
| Cazzato, 2000,54n = 78 | Lazor, 2000,13n = 48 | Basarakodu, 2007,12n = 57 | Barroso, 2007,120n = 33 | Yoo, 2011,121n = 100 | Drakopanagiotakis, 2011,6n = 61 | Nishino, 2014,122n = 26 | Onishi, 2016,123n = 75 | Okada, 2016,14n = 19 | Baha, 2018,2n = 56 | Saito, 2019,124n = 33 | Zhou, 2019,125n = 87 | Zhang, 2020,126n = 176 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) age (years) |
61 ± 12 | 61 ± 11 | 63 ± 15 (COP) 59 ± 15 (SOP) |
62 ± 10 | 54.8 ± 12.3 (CTD-OP)/56.0 ± 11.5 (COP) | 60.5 ± 13.6 | 62.5 (39–78) | 69.9 ± 10.3 | 61.9 ± 8 | 57.1 ± 12.7 | Relapse: 71 ± 10; No relapse: 74 ± 14 |
56.1 ± 10.4 (31–75) | Unilateral 55.9 ± 9.4 Bilateral 55.8 ± 10.0 |
| Sex (F) | 36 (46%) | 31 (65%) | 26 (46%) | 18 (55%) | 65 (65%) | 34 (56%) | 8 (31%) | 32 (43%) | 12 (63%) | 27 (48%) | 15 (45%) | 42 (48%) | 73 (41%) |
| Smokers | 53 (68%) | 14 (29%) | – | 10 (30%) | 15 (15%) | 33 (54%) | 1 (4%) | – | 7 (37%) | 33 (59%) | 14 (42%) | 24 (28%) | 55 (31%) |
| Lung disease | – | – | 12 (21%) | – | – | – | – | – | 4 (21%) | – | – | – | – |
| Fever | 49 (63%) | – | 16 (28%) | 26 (76%) | – | 39 (64%) | – | 42 (56%) | 15 (79%) | 24 (43%) | 22 (67%) | 40 (46%) | – |
| Cough | 41 (53%) | – | 26 (46%) | 29 (88%) | – | 40 (66%) | – | 44 (59%) | 8 (42%) | 40 (71%) | 27 (82%) | 73 (84%) | – |
| Dyspnoea | 45 (58%) | – | 45 (79%) | 19 (58%) | 85 (85%) | 38 (62%) | – | 17 (23%) | 6 (32%) | 37 (66%) | 20 (61%) | 54 (32%) | – |
| Asthenia | 30 (38%) | – | 16 (28%) | – | – | 44 (72%) | – | – | – | 36 (64%) | – | – | – |
| Weight loss | 10 (13%) | – | 8 (14%) | 14 (42%) | – | 17 (28%) | – | – | – | 14 (25%) | – | 9 (10%) | – |
| Flu-like symptoms | 21 (27%) | – | 2 (3.5%) | 7 (21%) | – | 15 (26%) arthralgia | – | – | – | – | – | – | – |
| Chest pain | 2 (3%) | – | 16 (28%) | 18 (52%) | – | 18 (30%) | – | – | – | 7 (12.5%) | 1 (3%) | 4 (5%) | – |
| Haemoptysis | 1 (1%) | – | – | 12% | – | – | – | – | – | 4 (7%) | – | 5 (6%) | – |
| Asymptomatic | 10 (13%) | – | – | – | – | – | 7 (9%) | – | – | – | – | ||
| Aetiology | 53 (68%) COP 25 (32%) SOP: 7 (9%) drugs 5 (6%) radiotherapy 5 (6%) CTD |
48 (100%) COP | 30 (53%) COP 27 (47%) SOP: 8 (14%) infections 7 (12%) CTD 7 (12%) drugs |
33 (100%) COP | 76 (76%) COP 24 (24%) CTD–OP. 7 (7%) RA 6 (6%) SS 3 (3%) PM |
40 (66%) COP 21 (34%) SOP: 6 (10%) drugs 5 (8%) solid tumours 4 (7%) CTD |
26 (100%) COP | 40 (53%) COP; 35 (47%) SOP: 18 (24%) SAD, 6 (8%) infections, 11 (15%) others |
19 (100%) SOP: 18 (95%) RA 1 (5%) bacterial infection |
37 (66%) COP 19 (34%) SOP: 4 (7%) RA, 3 (5%) SS, 1 (4%) SLE, 2 (4%) lymphoma |
33 (100%) COP | 87 (100%) COP | 176 (100%) COP |
COP: cryptogenic organizing pneumonia; COPD: chronic obstructive pulmonary disease; CTD: connective tissue disease; F, female; HBV: hepatitis B virus; IBD: inflammatory bowel disease; ILD: interstitial lung disease; M, male; OSAS: obstructive sleep apnoea syndrome; PMR: polymyalgia rheumatica; POEMS: peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasma-cells proliferative disorder and skin change syndrome; RA: rheumatoid arthritis; SAD: systemic autoimmune disease; SS: Sjögren syndrome; PM: polymyositis; SLE: systemic lupus erythematosus; SOP: secondary organizing pneumonia.